Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,2565,27-2,60
Msft0,74
Nokia3,453,5795-0,92
IBM0,13
Mercedes-Benz Group AG6666,020,49
PFE0,66
25.05.2024 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 24.05.2024 18:00:00
Camurus (Stockholm)
Závěr k 24.5.2024 Změna (%) Změna (SEK) Objem obchodů (SEK)
560,50 1,82 10,00 16 022 610
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 26.05.2024
Popis společnosti
Obecné informace
Název společnostiCamurus AB
TickerCAMX
Kmenové akcie:Ordinary Shares
RICCAMX.ST
ISINSE0007692850
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.03.2024
Počet zaměstnanců k 31.03.2024 218
Akcie v oběhu k 31.03.2024 57 623 618
MěnaSEK
Kontaktní informace
UliceIdeongatan 1A
MěstoLUND
PSČ223 62
ZeměSweden
Kontatní osobaFredrik Joabsson
Funkce kontaktní osobyChief Business Development Officer
Telefon46 462 865 730
Fax46462865739
Kontatní telefon46 462 865 747

Business Summary: Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Camurus AB revenues increased 37% to SEK390M. Net income increased 32% to SEK77.9M. Revenues reflect Sales of development related goods and services segment increase of 29% to SEK364.1M, European Union (Region)-Sweden (Country) segment increase of 31% to SEK205.9M, Asia including Oceania segment increase of 28% to SEK137.1M.
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 26.05.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, Chief Scientific Officer, DirectorFredrik Tiberg6112.05.202201.01.2003
Chief Financial OfficerJon Alonso5101.02.202201.02.2022
Senior Vice President R and DMarkus Johnsson5201.01.2009
Chief Technical OfficerTorsten Malmstroem56
Vice President - Regulatory AffairsAnnette Mattsson5801.01.2017
Vice President - Clinical DevelopmentAgneta Svedberg6101.01.2015
Chief Business Development OfficerFredrik Joabsson5201.01.2011
Chief Commercial OfficerRichard Jameson60
Global Head of Human ResourcesMaria Lundqvist5801.01.2021
Chief Medical OfficerAlberto Pedroncelli60